Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Breast Neoplasms

Triple Negative Breast Neoplasms

Breast Diseases

Skin Diseases

Antineoplastic Agents

All Drugs and Chemicals

Antirheumatic Agents

Anti-Infective Agents

Paclitaxel

Carboplatin

Cyclophosphamide

Docetaxel

Albumin-Bound Paclitaxel

Epirubicin

Taxane

Immunosuppressive Agents

Immunologic Factors

Antineoplastic Agents, Alkylating

Alkylating Agents

Anti-Bacterial Agents

Antibiotics, Antitubercular

Enzyme Inhibitors

Epirubicin plus Cyclophosphamide followed by Paclitaxel or Docetaxel

Epirubicin plus Cyclophosphamide followed by Paclitaxel or Docetaxel + Carboplatin

Epirubicin 90mg/m2, d1, q3w\*4 Cyclophosphamide: 600mg/m2, d1, q3w\*4

Epirubicin plus Cyclophosphamide

Paclitaxel: 80mg/m2, d1, qw\*12 or Docetaxel: 80-100mg/m2,d1,q3w\*4

Taxanes

Paclitaxel: 80mg/m2, d1,d8,d15, q4w\*4 Carboplatin AUC=2, d1,d8,d15, q4w\*4 or Docetaxel: 75mg/m2,d1,q3w\*4 plus Carboplatin AUC=5-6, d1, q3w\*4

Taxanes plus Carboplatin

Xiaosong Chen, Dr.

Yongan Chen

Xiangjin Chen, MD.

Debo Chen

Guolin Ye

Anqin Zhang, MD

Guoqiang Zhang

Qing Shao, MD.

Xiaodong Wang, MD.

Wu Jiang

Kejin Wu, MD.

Kunwei Shen, professor

Jialin Bao, MD.

QI He, MD.

Shanyu Guo, MD.

Meili Wang

Xiaohong Xie

Juanying Zhu, MD

Yong Shi, MD

Weizhu Wu, MD.

Zhanwen Li, MD.

Yu Guo

Weili Wu

Weili Ren

Zhian Li

Yuechu Dai, MD.

Yong Zeng

Xia Qiu, MD.

To compare disease-free survival (DFS) rate of adjuvant chemotherapy epirubicin-cyclophosphamide followed by weekly paclitaxel or docetaxel (EC-T), or weekly paclitaxel or docetaxel-carboplatin (EC-TCb) in triple-negative breast cancer.

This study plans to enroll triple-negative breast cancer patients who have complete tumor removal. Patients are randomized to receive either EC-wP/T or EC-wP/TCb adjuvant chemotherapy. For triple-negative breast cancer, a subgroup of triple-negative breast cancer has DNA repairement deficiency and adding carboplatin to paclitaxel may improve DFS on the basis of weekly paclitaxel adjuvant chemotherapy.

Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer

Epirubicin-Cyclophosphamide Followed by Taxanes or Taxanes Plus Carboplatin in Triple-Negative Breast Cancer：A Prospective, Randomized, Phase III Trial

to compare the disease-free survival among two treatment arms

to compare the overall survival among two treatment arms

to compare the neutropenia fever among two treatment arms

to compare the grade 3-4 side effects among two treatment arms

Shanghai Jiao Tong University School of Medicine

professor

Spots Global Cancer Trial Database for epirubicin plus cyclophosphamide